| T6129 |
GSK-1070916
|
942918-07-2
|
98.51%
|
|
|
GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM. It displays >100-fold selectivity against the ...
|
| T34787 |
TAS-119
|
1453099-83-6
|
98.69%
|
|
|
TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95 nM...
|
| T14927 |
Centrinone
|
1798871-30-3
|
98.76%
|
|
|
Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
|
| T6068 |
MK-5108
|
1010085-13-8
|
98.76%
|
|
|
MK-5108 (VX-689) is a highly potent and specific Aurora-A kinase inhibitor with an IC50 value of 0.064 nM.
|
| T1886 |
TAK-632
|
1228591-30-7
|
98.92%
|
|
|
TAK-632 is a potent pan-Raf inhibitor.
|
| T17267 |
XL228
|
898280-07-4
|
98.92%
|
|
|
XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).
|
| T6338 |
PHA-680632
|
398493-79-3
|
99.03%
|
|
|
PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGF...
|
| T6315 |
MLN8054
|
869363-13-3
|
99.05%
|
|
|
MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.
|
| T6077 |
ZM-447439
|
331771-20-1
|
99.11%
|
|
|
ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective f...
|
| T9040 |
Aurora kinase inhibitor-2
|
331770-21-9
|
99.15%
|
|
|
Aurora kinase inhibitor-2 (IUN-70219) is a cell-permeable anilinoquinazoline that inhibit the activity of Aurora A (IC50 = 0.39 M).
|
| T6039 |
TAK-285
|
871026-44-7
|
99.17%
|
|
|
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Auro...
|
| T8866 |
GW779439X
|
551919-98-3
|
99.23%
|
|
|
GW779439X is an inhibitor of CDK.
|
| T2471 |
MK-8745
|
885325-71-3
|
99.31%
|
|
|
MK-8745 is a potent and selective Aurora A inhibitor.
|
| T6057 |
URMC-099
|
1229582-33-5
|
99.32%
|
|
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
| T2709 |
TAK-901
|
934541-31-8
|
99.39%
|
|
|
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others....
|
| T15815 |
LY3295668
|
1919888-06-4
|
99.44%
|
|
|
LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.
|
| T5S0802 |
Palmatine
|
3486-67-7
|
99.49%
|
|
|
1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palma...
|
| T50110 |
CD532
|
1639009-81-6
|
99.49%
|
|
|
CD532 is A highly potent Aurora A kinase inhibitor with an IC50 value of 45 nM. CD532 can block Aurora A kinase activity, drive MYCN degradation, and can directl...
|
| T41256 |
SP-96
|
2682114-54-9
|
99.52%
|
|
|
SP-96 is a highly effective and selective inhibitor of Aurora B with an IC50 of 0.316 nM. SP-96 shows selective growth inhibition in NCI60 screening, including M...
|
| T15454 |
GW843682X
|
660868-91-7
|
99.56%
|
|
|
GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).
|
